INHIBRX BIOSCIENCES, INC. Amortization of Debt Issuance Costs and Discounts
INHIBRX BIOSCIENCES, INC. (INBX) reported Amortization of Debt Issuance Costs and Discounts of $2.02 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:AmortizationOfFinancingCostsAndDiscounts · last filed 2026-08-13
- INHIBRX BIOSCIENCES, INC. amortization of debt issuance costs and discounts for the quarter ending 2026-06-30 was $1.29M, a 106.23% increase year-over-year.
- INHIBRX BIOSCIENCES, INC. amortization of debt issuance costs and discounts for the quarter ending 2026-03-31 was $732.00K, a 37.34% increase year-over-year.
- INHIBRX BIOSCIENCES, INC. amortization of debt issuance costs and discounts for the quarter ending 2025-12-31 was $642.00K.
- INHIBRX BIOSCIENCES, INC. amortization of debt issuance costs and discounts for the quarter ending 2025-09-30 was $638.00K.
- INHIBRX BIOSCIENCES, INC. amortization of debt issuance costs and discounts for fiscal 2025 was $2.44M, a 18.11% increase from fiscal 2024.
- INHIBRX BIOSCIENCES, INC. amortization of debt issuance costs and discounts for fiscal 2024 was $2.06M, a 57.85% decline from fiscal 2023.
- INHIBRX BIOSCIENCES, INC. amortization of debt issuance costs and discounts for fiscal 2023 was $4.90M.
| Period end | Amortization of Debt Issuance Costs and Discounts 3 month | Amortization of Debt Issuance Costs and Discounts 6 month | Amortization of Debt Issuance Costs and Discounts 9 month | Amortization of Debt Issuance Costs and Discounts 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $2.02M 10-Q · filed 2026-08-13 | $2.67M derived: sum of 3 quarters · filed 2026-08-13 | $3.30M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $732.00K 10-Q · filed 2026-05-14 | $1.37M derived: sum of 2 quarters · filed 2026-05-14 | $2.01M derived: sum of 3 quarters · filed 2026-05-14 | $2.64M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $642.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $1.28M derived: sum of 2 quarters · filed 2026-03-19 | $1.91M derived: sum of 3 quarters · filed 2026-08-13 | $2.44M 10-K · filed 2026-03-19 |
| 2025-09-30 | $638.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $1.26M derived: sum of 2 quarters · filed 2026-08-13 | $1.80M 10-Q · filed 2025-11-14 | $1.80M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $626.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $1.16M 10-Q · filed 2026-08-13 | $1.16M derived: sum of 3 quarters · filed 2026-08-13 | $1.16M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $533.00K 10-Q · filed 2026-05-14 | $533.00K derived: sum of 2 quarters · filed 2026-05-14 | $533.00K derived: sum of 3 quarters · filed 2026-05-14 | $1.36M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $0.00 derived: sum of 2 quarters · filed 2026-03-19 | $823.00K derived: sum of 3 quarters · filed 2026-03-19 | $2.06M 10-K · filed 2026-03-19 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $823.00K derived: sum of 2 quarters · filed 2025-11-14 | $2.06M 10-Q · filed 2025-11-14 | $3.31M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $823.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $2.06M 10-Q · filed 2025-08-13 | $3.31M derived: sum of 3 quarters · filed 2025-08-13 | $4.55M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $1.24M 10-Q · filed 2025-05-14 | $2.49M derived: sum of 2 quarters · filed 2025-05-14 | $3.73M derived: sum of 3 quarters · filed 2025-05-14 | |
| 2023-12-31 | $1.25M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $2.49M derived: sum of 2 quarters · filed 2025-03-17 | $4.90M 10-K · filed 2025-03-17 | |
| 2023-09-30 | $1.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $3.65M 10-Q · filed 2024-11-14 | ||
| 2023-06-30 | $2.41M 10-Q · filed 2024-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |